Skip to content
Apogee Biotechnology Corporation

Apogee Biotechnology Corporation

  • Welcome
  • News
  • Technology
  • Lead Compound
  • Contact Us / Policies

Initiation of Phase IIa Study with ABC294640 (opaganib) for Cholangiocarcinoma at Mayo Clinic and MD Anderson

Posted bylwm100 December 22, 2017May 20, 2020 Leave a comment on Initiation of Phase IIa Study with ABC294640 (opaganib) for Cholangiocarcinoma at Mayo Clinic and MD Anderson

https://www.redhillbio.com/RedHill/Templates/showpage.asp?DBID=1&LNGID=1&TMID=178&FID=1365&PID=0&IID=6163

Posted bylwm100December 22, 2017May 20, 2020Posted inUncategorized

Post navigation

Previous Post Previous post:
Peer-reviewed publication of the positive ABC294640 (opaganib) Phase 1 study results in advanced solid tumors.
Next Post Next post:
Presentation on ABC294640 (opaganib) for Multiple Myeloma

Leave a comment

Cancel reply

Your email address will not be published. Required fields are marked *

Apogee Biotechnology Corporation, Proudly powered by WordPress.